TL;DR
The developed stearic acid/lauric acid binary eutectic thermoresponsive lipid nanoparticles exhibited favorable physicochemical properties, thermoresponsive drug release, biocompatibility, and enhanced anticancer activity, highlighting their potential for thermoresponsive doxorubicin delivery in cancer therapy.
The NLC formulations studied, particularly NX-ST, effectively enhanced HU's therapeutic performance by improving stability, delivery efficiency, and anticancer activity.
The developed transethosomal system showed favorable physicochemical properties, sustained drug release, stability, antioxidant and antimicrobial activity, and significant cytotoxicity against melanoma cells, which support its potential as a multifunctional topical platform for localized melanoma therapy and provide a...
The FA-loaded NIPAM-MAA nanogel effectively addresses the physicochemical limitations of fusidic acid, including poor solubility and rapid clearance, by providing a regulated and sustained release profile, however, formal cytocompatibility and in vivo efficacy evaluations are required before clinical translation.
Controlled drug release and enhanced cellular accumulation are critical strategies for improving the efficacy of mesoporous silica nanoparticle (MSN) carriers in cancer therapy. This study describes the development of a hybrid nanocarrier (MLBF) consisting of an MSN core encapsulated within a lipid bilayer modified w...
The synergistic combination of green synthesis, magnetic targeting capability, pH-triggered drug release, and superior anticancer efficacy highlights Fe3O4@PEG-CUR-NPs as a promising nanotherapeutic platform for precision cancer treatment and advanced biomedical applications.
Controlled and targeted drug delivery to the diseased site can significantly reduce systemic toxicity and improve therapeutic efficacy by enhancing cellular uptake. In this study, we report the development of biocompatible sodium bis(2-ethylhexyl) sulfosuccinate (AOT)-based nanovesicles for the co-delivery of hydroph...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
